Related references
Note: Only part of the references are listed.Immunoactivating the tumor microenvironment enhances immunotherapy as predicted by integrative computational model
Aleksander S. Popel
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients
Tian Zhang et al.
ONCOIMMUNOLOGY (2020)
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Sarabjot Pabla et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Future of Immunotherapy in the Treatment of Cancer
Lisa A. Kottschade
Seminars in Oncology Nursing (2019)
1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
A Marabelle et al.
ANNALS OF ONCOLOGY (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer A Meta-analysis and Individual Patient-Level Analysis
Yunfang Yu et al.
JAMA NETWORK OPEN (2019)
Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
Conor E. Steuer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors
Jeffrey M. Conroy et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Carl Morrison et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Share Paper
